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Antipsychotics, mood stabilisers, and risk of violent crime
Seena Fazel, Johan Zetterqvist, Henrik Larsson, Niklas Långström, Paul Lichtenstein
Summary
Background Antipsychotics and mood stabilisers are prescribed widely to patients with psychiatric disorders 
worldwide. Despite clear evidence for their eﬃ  cacy in relapse prevention and symptom relief, their eﬀ ect on some 
adverse outcomes, including the perpetration of violent crime, is unclear. We aimed to establish the eﬀ ect of 
antipsychotics and mood stabilisers on the rate of violent crime committed by patients with psychiatric disorders in 
Sweden.
Methods We used linked Swedish national registers to study 82 647 patients who were prescribed antipsychotics or 
mood stabilisers, their psychiatric diagnoses, and subsequent criminal convictions in 2006–09. We did within-
individual analyses to compare the rate of violent criminality during the time that patients were prescribed these 
medications versus the rate for the same patients while they were not receiving the drugs to adjust for all confounders 
that remained constant within each participant during follow-up. The primary outcome was the occurrence of violent 
crime, according to Sweden’s national crime register.
Findings In 2006–09, 40 937 men in Sweden were prescribed antipsychotics or mood stabilisers, of whom 2657 (6·5%) 
were convicted of a violent crime during the study period. In the same period, 41 710 women were prescribed these 
drugs, of whom 604 (1·4 %) had convictions for violent crime. Compared with periods when participants were not on 
medication, violent crime fell by 45% in patients receiving antipsychotics (hazard ratio [HR] 0·55, 95% CI 0·47–0·64) 
and by 24% in patients prescribed mood stabilisers (0·76, 0·62–0·93). However, we identiﬁ ed potentially important 
diﬀ erences by diagnosis—mood stabilisers were associated with a reduced rate of violent crime only in patients with 
bipolar disorder. The rate of violence reduction for antipsychotics remained between 22% and 29% in sensitivity 
analyses that used diﬀ erent outcomes (any crime, drug-related crime, less severe crime, and violent arrest), and was 
stronger in patients who were prescribed higher drug doses than in those prescribed low doses. Notable reductions in 
violent crime were also recorded for depot medication (HR adjusted for concomitant oral medications 0·60, 
95% CI 0·39–0·92).
Interpretation In addition to relapse prevention and psychiatric symptom relief, the beneﬁ ts of antipsychotics and 
mood stabilisers might also include reductions in the rates of violent crime. The potential eﬀ ects of these drugs on 
violence and crime should be taken into account when treatment options for patients with psychiatric disorders are 
being considered.
Funding The Wellcome Trust, the Swedish Prison and Probation Service, the Swedish Research Council, and the 
Swedish Research Council for Health, Working Life and Welfare.
Copyright © Fazel et al. Open Access article distributed under the terms of CC BY.
Introduction
Antipsychotic drugs and mood stabilisers are widely 
prescribed for a range of psychiatric disorders, including 
schizophrenia and related disorders, bipolar disorder, 
severe depression, and other diagnoses. In 2007, an 
estimated 3·9 million Americans (1·3% of the population) 
purchased antipsychotics at a total cost of US$7·4 billion, 
which represents a three-fold increase within a decade.1 A 
similar pattern exists in other high-income countries:2,3 
antipsychotic prescriptions in the UK increased by 82% 
between 1998 and 2010 (a 5·1% rise per year),4 and the 
number of such prescriptions tripled in Australia between 
2000 and 2011.5 Large increases in prescriptions for mood 
stabilisers have also been recorded,5,6 with 0·3–0·4% of 
people in the USA prescribed these drugs in 2007.7 
Systematic reviews of trial data have shown that 
antipsychotics and mood stabilisers have beneﬁ cial 
eﬀ ects on relapse and readmission rates in schizophrenia,8 
bipolar disorder,9,10 treatment-resistant depression,11 and 
borderline personality disorder.12 However, evidence 
about the eﬀ ects of pharmacotherapy on other important 
outcomes,13,14 including violent behaviour,15 is scarce.
The perpetration of interpersonal violence and its 
consequences are among the most important adverse 
outcomes for patients with psychiatric disorders.16 
Recent reviews suggest that the relative risk of violence 
against other people is four-times higher in patients 
with schizophrenia and related psychoses than in the 
general population,17 and estimated absolute rates of 
violence are 28% within 1 year of discharge from US 
inner city hospitals18 and 5% in patients who are not 
admitted to hospital.19 In patients with bipolar disorder, 
rates of violence are substantially increased in cases of 
substance misuse.20
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Consequently, the reduction of violence risk in 
psychiatric patients is a core component of clinical care, 
and clinical guidelines in the USA and UK recommend 
risk assessment of violence in patients with 
schizophrenia.21,22 However, evidence for eﬀ ective 
therapeutic approaches to manage the risk of violence is 
not strong, has mostly been generalised from oﬀ enders 
without mental disorders, and is focused on psychological 
interventions.23 According to reviews24,25 and clinical 
guidelines,26 the existing evidence base for pharmacological 
strategies to reduce violence risk is weak or inconclusive. 
Furthermore, although depot injection of antipsychotics 
seems to reduce relapse rates further compared with 
orally administered antipsychotics,27,28 whether or not such 
beneﬁ ts extend to reductions in violence risk is unknown. 
Randomised clinical trials of drugs in which violence is 
investigated are scarce because low outcome rates mean 
that such trials would have to be unfeasibly large to show 
diﬀ erences between the intervention and control groups. 
Furthermore, aggressive or hostile patients are less likely 
to be recruited, consent, or remain in the study than are 
patients without such traits, and such trials could be 
diﬃ  cult to justify ethically because of the immediate need 
for treatment in some patients. Pharmacoepidemiological 
approaches oﬀ er an alternative in that they compare rates 
of violence in patients taking antipsychotics with those in 
people who are not. However, this design is limited by 
confounding by indication—the patients taking such 
drugs have diﬀ erent background risk factors for violence 
to those who are not on medication. Propensity scoring 
attempts to adjust for this; nevertheless, residual 
confounding is likely to bias results.29 This limitation is 
partly addressed by within-individual designs, in which 
rates of violence when patients are on medication are 
compared with the rates when they are not taking 
medication. This design accounts for confounders that 
remain stable within the same patient, although such 
studies cannot prove causality because other time-varying 
factors could be associated with adherence to treatment.
Therefore, we undertook a national pharmaco-
epidemiological study using data from high-quality 
nationwide registers during 2005–09, in which we did 
within-individual analyses. We tested four hypotheses: 
antipsychotics and mood stabilisers reduce rates of 
violent oﬀ ending in patients prescribed these 
medications; rate reductions diﬀ er according to major 
diagnostic categories; combination treatment with 
antipsychotics and mood stabilisers further improves 
violent outcomes; and depot antipsychotics reduce the 
risk of violence by a greater extent than do oral 
antipsychotics.
Methods
Study design and patients
We obtained data for this study through linkage of 
national longitudinal population-based registers in 
Sweden; unique personal identiﬁ cation numbers enabled 
accurate data linkage across registers.30 We initially 
included all people in Sweden born between Jan 1, 1961, 
and Dec 31, 1990 (1 944 548 men and 1 858 984 women), so 
that all participants were at least 15 years of age (the 
Swedish age of criminal responsibility) at the start of 
follow-up in July, 2005. From this population, we 
identiﬁ ed our primary sample: people prescribed mood 
stabilisers or antipsychotics according to the Swedish 
Prescribed Drug Register. This register includes 
information about all prescribed and dispensed 
medication since July, 2005, including the exact dates of 
the dispensed prescription,31 and is reported to be 
complete, with less than 0·3% of entries having missing 
patient identity data.31 We identiﬁ ed violent criminality 
through the national crime register, which includes 
convictions in all Swedish district courts since 1973.32 For 
sensitivity analyses, we also used the register of persons 
suspected of oﬀ ences, which includes people who are 
suspected of crime after a completed investigation by 
police, customs authority, or prosecution service.32 The 
crime register has excellent coverage: in a 13-year study, 
only 0·05% of cases had incomplete personal identiﬁ ers.33 
We also identiﬁ ed emigrations and deaths by linking 
individuals to the migration and cause of death registers, 
so that the actual time at risk for crime outcomes could 
be accounted for. Periods in prison were accounted for by 
linkage to the prison register, and times spent in 
psychiatric hospitals were estimated with the National 
Patient Register, which includes data for all psychiatric 
hospital admissions since 1973 (and for outpatient care 
since 2001).34
The study was approved by the Regional Ethics 
Committee at Karolinska Institutet, Sweden.
Deﬁ nitions and measures
We extracted data about treatment with antipsychotics 
and mood stabilisers, identiﬁ ed in the Swedish Prescribed 
Drug Register according to the Anatomical Therapeutic 
Chemical (ATC) classiﬁ cation system. Antipsychotics 
were deﬁ ned as drugs with ATC codes N05A, excluding 
lithium (N05AN01) and clozapine (N05AH02). Mood 
stabilisers were deﬁ ned as valproic acid or sodium 
valproate (N03AG01), lamotrigine (N03AX09), 
carbamazepine (N03AF01), oxcarbazepine (N03AF02), 
and lithium. Clozapine was coded separately because it is 
licensed only for patients with treatment-resistant 
psychosis (which has shown inadequate response to 
treatment in two adequate trials—ie, those of 4 weeks at 
optimum dose—of other antipsychotics)26 and necessitates 
regular blood testing, which suggests that patients who 
are prescribed this drug are a selected group. Furthermore, 
clozapine’s eﬃ  cacy is signiﬁ cantly higher than that of 
other antipsychotics.35 Antipsychotic depot preparations 
were identiﬁ ed as injections administered every 2 weeks 
or longer.
We deﬁ ned start of treatment as the date of the ﬁ rst 
prescription, and end of treatment as the date of the ﬁ nal 
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prescription during the study period. These dates are the 
days on which the prescriptions were collected. A patient 
was deﬁ ned as receiving treatment during the time 
interval between two dispensed prescriptions of 
medication, unless prescriptions were issued more than 
4 months apart. We chose this time interval because in 
routine psychiatric practice, oral medications are unlikely 
to be dispensed for more than 3 months at a time (the 
so-called 90-day rule in Sweden). Thus, a treatment 
period was deﬁ ned as a sequence of at least two 
prescriptions, with no more than 4 months between any 
two consecutive prescriptions. During periods of more 
than 4 months without any new prescription, the patient 
was judged to be oﬀ  treatment. However, for antipsychotic 
depots, which are administered not by patients but by 
health-care staﬀ , we allowed an interval of up to 1 year 
between two consecutive prescriptions in a treatment 
period. Patients who received a prescription only once 
(n=20 700) were judged to be oﬀ  treatment throughout 
the study period, and did not contribute to our within-
individual estimates. To establish whether participants 
were receiving treatment at the start and end of follow-
up, we needed information about prescription dates in 
the 4 months before and the 4 months after follow-up. 
Since the Prescribed Drug Register covered the period 
July 1, 2005–June 30, 2010, the start of follow-up was set 
as Jan 1, 2006 to avoid any selection bias with an earlier 
date. We had register information until Dec 31, 2009, 
which was set as end of follow-up.
We also used deﬁ ned daily doses to analyse the eﬀ ects 
of medication dose, in which we compared the eﬀ ects of 
0, 1, and 2 deﬁ ned daily doses on conviction for violence 
(appendix).
Outcomes  
The primary outcome was conviction for a violent 
crime—deﬁ ned as any criminal conviction for homicide, 
assault, robbery, arson, any sexual oﬀ ence, illegal threats, 
or intimidation36—according to data from the national 
crime register. We did not include suspected violent 
crime in the main analyses. We used the date of the 
committed crime; for cases in which a time window was 
given for the date of the crime, we used the earliest date. 
For 77% of the crimes, we could establish the date with 
an accuracy of 1 week. We excluded cases for which no 
speciﬁ c crime date had been recorded (119 violent 
convictions [1·17%]) because conviction dates can be 
much later than crime dates and might distort the correct 
ordering of events.
Diagnostic categories
We used the National Patient Register to identify patients 
diagnosed with schizophrenia, bipolar disorder, other 
psychotic disorders (apart from schizophrenia and bipolar 
disorder), and depression. In accordance with the 
International Classiﬁ cation of Diseases tenth revision 
diagnostic guidelines, we used a hierarchical diagnostic 
system—patients with schizophrenia at any time were 
diagnosed with schizophrenia, followed by bipolar 
disorder, and then other psychoses. This approach has 
also been used in previous studies (see appendix for 
diagnostic codes).37 We included depression because 
mood stabilisers and antipsychotics are used frequently 
in its treatment. The diagnostic validity is strong for 
schizophrenia (concordance rates of 86% in comparisons 
with ﬁ le reviews by psychiatrists)38 and bipolar disorder 
(concordance of 92%).39
Statistical analyses
Initially, we did between-individuals analyses, which 
included all people who had been on medication at some 
point during the 4 years of the study, and we compared 
violent crime rates in patients on medication with those 
who were not on medication. Medication groups were 
combined into one time-dependent binary covariate, 
with one level for any medication and another for no 
medication. To account for the correlations between 
periods within the same patient, we calculated robust 
standard errors. We adjusted the between-individual 
analysis for sex and age (as a time-dependent covariate).
However, our main approach was to undertake within-
individual analyses. We did these analyses with stratiﬁ ed 
Cox regression—we entered each patient as a separate 
stratum in the analysis, which adjusts for all confounders 
that remain constant within each person during follow-
up. Three medication groups (anti psychotics, mood 
stabilisers, and clozapine) were coded as separate time-
dependent covariates in the same model. For each 
patient, we compared the crime rate while on medication 
with the crime rate while oﬀ  treatment for each 
medication group, with adjustment for the other two 
medication groups. We also used a similar model in 
which all drugs were combined into one time-dependent 
binary covariate. We did not adjust for age in within-
individual analyses because this approach can provide 
erroneous estimates.40 Furthermore, the risk of 
confounding by age was judged to be low because the 
maximum length of follow-up was 4 years in a cohort 
with an average age of 31 years at the start of follow-up. 
More details about the statistical methods used are 
available in a related publication.41
Sensitivity analyses  
To establish whether the reported associations could be 
explained by selection eﬀ ects and to test the robustness 
of our ﬁ ndings, we investigated diﬀ erent outcomes, 
which included any crime, less severe crime (deﬁ ned as 
crimes not leading to custodial sentences), and drug-
related crime. Additionally, we used the national register 
of persons suspected of oﬀ ences (or suspicions register), 
which will have included those people who were 
subsequently convicted. In Sweden, people are convicted 
of crimes irrespective of their mental disorder, although 
their sentencing will be aﬀ ected by psychiatric evidence. 
See Online for appendix
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Nevertheless, the probability of being convicted could be 
aﬀ ected by socioeconomic conditions, living area, age, or 
psychiatric history.
Additionally, within the cohort of patients prescribed 
antipsychotics or mood stabilisers, we studied the eﬀ ects 
of being prescribed a selective serotonin reuptake 
inhibitor antidepressant on violent crime. This analysis 
was one approach to handle the possible non-speciﬁ c 
eﬀ ects of medication prescription on oﬀ ending, such as 
regular reviews by health-care staﬀ  and links to other 
medical and social services. In other sensitivity analyses, 
we assessed the eﬀ ects of a history of violent crime 
(before Jan 1, 2006), dose of medication, timing of 
medication, censoring of periods of hospital stay, age at 
start of follow-up, and possible adherence eﬀ ects (see 
appendix for details).
Role of the funding source  
The funders of the study had no role in the design and 
conduct of the study, data gathering, management, 
analysis, and interpretation; or in the preparation, review, 
or approval of the report. JZ had full access to all the data 
in the study and, with SF, takes responsibility for the 
integrity of the data and the accuracy of the data analysis.
Results
Of the 1 944 548 men and 1 858 984 women born in 
Sweden between 1961 and 1990, we identiﬁ ed 40 937 men 
and 41 710 women who were prescribed any antipsychotic 
or mood stabiliser between Jan 1, 2006, and Dec 31, 2009, 
Thus, 2·1% of the men and 2·2% of the women had 
been prescribed at least one of these drugs. Table 1 shows 
the baseline characteristics of these patients. The average 
age of the sample population at start of follow-up was 
31·7 years for men and 31·3 years for women. During 
the study period, 2657 men were convicted of 4166 violent 
crimes, and 604 women convicted of 782 violent crimes, 
in this cohort.
First, we did between-individual analyses, in which we 
compared rates of violent crimes during periods on 
medication compared with periods not on medication 
in a cohort of 82 647 patients who had at least one period 
on medication during follow-up. In a Cox regression 
model, the violent crime rate was reduced by an 
estimated 64% for any antipsychotic or mood stabilisers 
(hazard ratio [HR] 0·36, 95% CI 0·34–0·39; table 2). 
When we made adjustments for other classes of drugs, 
we also noted speciﬁ c reductions in violent crime for 
mood stabilisers, antipsychotics (apart from clozapine), 
and clozapine (table 2; see appendix p 9 for extended 
Kaplan-Meier graphs).
To account for confounders that are constant within 
each patient during follow-up, we did within-individual 
analyses to compare rates of violent crime in the same 
individual when they were both on and oﬀ  medication 
(table 2). We noted substantially lower rates of violent 
crime when any of the three classes of medication had 
been prescribed, speciﬁ cally for antipsychotics and mood 
stabilisers (table 2). Clozapine was also associated with a 
reduced rate of violent crime (table 2), although this 
decrease was not signiﬁ cant because of the small number 
of patients (2178) who received this drug. These hazard 
ratios did not change substantially when we censored for 
periods of hospital stay (appendix p 3).
In our within-individual analyses, we noted that 
prescription of medication was associated with similar 
reductions in any crime, drug-related crime, less severe 
crime, and suspected violent crime, including signiﬁ cant 
reductions associated with clozapine for all outcomes 
except drug-related crime (table 3). Second, diﬀ erences 
in rates of violent crime were negligible between patients 
Men 
(n=40 937)
Women 
(n=41 710)
Person-years at risk 159 501 163 926
Age group (years)
15–24 9979 (24%) 11 105 (27%)
25–39 21 269 (52%) 21 151 (51%)
≥40 9689 (24%) 9454 (23%)
Civil status
Unknown 722 (2%) 751 (2%)
Unmarried 31 937 (78%) 27 584 (66%)
Married 5637 (14%) 8765 (21%)
Divorced 2638 (6%) 4610 (11%)
Widowed 3 (<1%) 0
Living in metropolitan area 8123 (20%) 7878 (19%)
Employed 14 636 (36%) 15 550 (37%)
Studying 4828 (12%) 7598 (18%)
Median family-adjusted income in 2006 
US$
15 497 
(12 434)
14 190 
(10 868)
Medications taken in 2006
Mood stabilisers 14 753 (36%) 15 528 (37%)
Antipsychotics 15 757 (38%) 14 283 (34%)
Clozapine 1360 (3%) 818 (2%)
Antidepressants (N06A) 14 420 (35%) 18 926 (45%)
Hypnotics/anxiolytics (N05B, N05C) 16 431 (40%) 19 400 (47%)
Stimulants (N06BA) 959 (2%) 679 (2%)
Drug used in addictive disorders (N07B) 1931 (5%) 1125 (3%)
Psychiatric diagnosis 
Any psychotic disorder 17 532 (43%) 16 646 (40%) 
Schizophrenia 6015 (15%) 3110 (7%)
Bipolar disorder 4303 (11%) 7615 (18%)
Other psychotic disorder 7214 (18%) 5921 (14%)
Depression 5731 (14%) 8563 (21%)
Antisocial personality disorder 588 (1%) 196 (<1%)
Other personality disorder 
(except antisocial personality disorder)
5517 (13%) 8535 (20%)
Alcohol misuse 6707 (16%) 4771 (11%)
Drug misuse 7367 (18%) 5632 (14%)
Data are n (%) or median (SD). 
Table 1: Background characteristics of patients prescribed antipsychotics 
and mood stabilisers in Sweden, 2006–09
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with previous violent convictions (9382 patients) and 
those without such convictions (73 261 patients) 
(appendix p 4). In patients with psychotic disorders, 
statistical power was low to test for violent crime, but we 
noted a trend towards larger reductions in rates of 
violent crime in those without violent criminal histories 
(appendix p 4). Third, we recorded little diﬀ erence in the 
violent crime risk depending on the order of medication. 
Patients who received treatment and then discontinued 
had similar odds of committing violent crime to those 
who started their medication after a period of non-
treatment (odds ratio [OR] 0·75, 95% CI 0·59–0·95 vs 
OR 0·74, 95% CI 0·59–0·94). No apparent diﬀ erences 
were recorded by age for antipsychotics, although a 
trend towards stronger associations with mood 
stabilisers in patients older than 40 years should be 
investigated further (appendix p 3). Finally, we recorded 
stronger associations between medication and violent 
crime reduction with higher doses of prescribed 
antipsychotics (p=0·019), but this association was not 
signiﬁ cant for mood stabilisers (p=0·127) or clozapine 
(p=0·255) (appendix p 5). To address adherence to 
treatment, we recorded no diﬀ erences in the rate of 
violence within the ﬁ rst 45 days after the start of 
treatment (short-term eﬀ ect) compared with that after 
45 days (long-term eﬀ ect; appendix p 6).
We calculated within-individual estimates for diagnostic 
subgroups. Rates of violent crime were signiﬁ cantly 
reduced in both male and female patients taking 
antipsychotics (excluding clozapine) who had diagnoses 
of schizophrenia, bipolar disorder, and other psychoses 
(table 4; see appendix p 7 for results by sex). For mood 
stabilisers, there was a signiﬁ cant reduction in violent 
crime in bipolar disorder in men but not in women 
(table 4, appendix p 7).
In our analysis of combination treatment, for which 
we used within-individual and between-individual 
approaches, we noted a signiﬁ cant decrease in the rate of 
violent crime when an antipsychotic was added to a 
mood stabiliser but not when a mood stabiliser was 
added to an antipsychotic (table 5; see appendix p 8 for 
results by sex).
To investigate depot antipsychotics, we separated these 
drugs from oral antipsychotics and restricted the cohort 
to patients with at least one prescription of depot 
Any of the three 
drug types 
Mood stabiliser Antipsychotic Clozapine
Within-individual* 0·57 (0·50–0·65) 0·76 (0·62–0·93) 0·55 (0·47–0·64) 0·53 (0·16–1·74)
Between-individual† 0·36 (0·34–0·39) 0·32 (0·28–0·35) 0·60 (0·54–0·65) 0·10 (0·05–0·19)
Data are hazard ratio (95% CI). In total, 4948 convicted violent crimes were committed. * The within-individual analyses 
are adjusted by other psychotropic medications (mood stabilisers, antipsychotics, or clozapine). †The between-individual 
analyses are adjusted by age, sex, and concomitant use of other psychotropic medications.
Table 2: Hazard ratios for the association between psychotropic medication and violent crime in a Swedish 
population cohort of 82 647 patients with prescriptions
Crimes in 
study cohort 
(n)
Mood stabiliser Antipsychotic Clozapine
Any crime (convictions) 29 496 0·83 (0·77–0·90) 0·78 (0·74–0·83) 0·53 (0·33–0·86)
Drug-related crime (convictions) 10 389 0·68 (0·58–0·79) 0·71 (0·65–0·79) 0·41 (0·15–1·13)
Less severe crimes* (convictions) 23 801 0·81 (0·74–0·88) 0·77 (0·73–0·82) 0·55 (0·32–0·97)
Violent crime (suspicions†) 16 069 0·87 (0·78–0·96) 0·74 (0·68–0·79) 0·43 (0·26–0·72)
Data are n or hazard ratio (95% CI). *Less severe crime were those that did not lead to custodial sentences. †Suspicions 
were crimes that led to an arrest and preliminary investigation.
Table 3: Hazard ratios for diﬀ erent crime outcomes in 82 647 patients prescribed mood stabilisers, 
antipsychotics, and clozapine, compared with periods when these same patients are not on medication 
(within-individual analyses)
Individuals in 
cohort (n)
Crimes in 
cohort (n)
Antipsychotic Mood stabiliser
Any psychotic disorder* 34 178 2445 0·50 (0·41–0·61) 0·65 (0·48–0·89)
Schizophrenia 9 125 542 0·65 (0·45–0·93) 1·17 (0·51–2·71)
Bipolar disorder 11 918 494 0·52 (0·29–0·92) 0·44 (0·28–0·70)
Other psychotic disorders† 13 135 1409 0·43 (0·33–0·55) 0·91 (0·54–1·53)
Depression 14 294 848 0·77 (0·51–1·15) 0·91 (0·55–1·52)
Data are n or hazard ratio (95% CI). All analyses are adjusted for clozapine medication. Analyses were underpowered to 
investigate clozapine. *Includes schizophrenia, bipolar disorder, and other psychotic disorders. †Excludes both schizophrenia 
and bipolar disorder.
Table 4: Hazard ratios for violent crime in patients with diﬀ erent psychiatric disorders who have been 
prescribed antipsychotics and mood stabilisers (within-individual analyses)
Patient group Number of individuals 
(number of crimes)
Within-individual 
estimates
Between-individual 
estimates
Addition of an antipsychotic 
during periods on mood stabilisers
Patients ever prescribed both mood stabiliser 
and antipsychotic during follow-up
11 654 (228) 0·27 (0·09–0·79) 0·69 (0·50–0·96)
Addition of a mood stabiliser 
during periods on antipsychotics
Patients ever prescribed both mood stabiliser 
and antipsychotic during follow-up
11 654 (219) 0·77 (0·32–1·85) 0·74 (0·55–1·01)
Antipsychotic depot Prescribed depot antipsychotic during follow-up 4904 (1162) 0·67 (0·45–1·01) 0·38 (0·32–0·54)
Antipsychotic depot* Prescribed depot antipsychotic during follow-up 4904 (1162) 0·60 (0·39–0·92) 0·30 (0·23–0·39)
Antipsychotic oral medication Prescribed oral antipsychotic during follow-up 47 235 (3864) 0·53 (0·45–0·62) 0·42 (0·38–0·46)
SSRI medication Prescribed mood stabiliser, antipsychotic, or 
clozapine during follow-up
82 647 (4948) 1·15 (0·96–1·37) 0·95 (0·86–1·06)
Data are n or hazard ratio (95% CI). SSRI=selective serotonin reuptake inhibitor. *Adjusted for concomitant use of oral antipsychotics, mood stabilisers, and clozapine.
Table 5: Hazard ratios for the association between violent crime and diﬀ erent exposures to psychotropic medications
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antipsychotics during follow-up (table 5, and appendix 
p 8 by sex). In within-individual analyses, when adjusting 
for oral antipsychotics and mood stabilisers, we noted a 
signiﬁ cant reduction in violence overall (table 5).
Finally, we assessed the possible eﬀ ects of selective 
serotonin reuptake inhibitor antidepressants within the 
group of patients prescribed antipsychotics, mood 
stabilisers, or both. Here, when we compared rates of 
violent crime convictions when individuals were on 
selective serotonin reuptake inhibitors compared with 
when these same individuals were not (irrespective of 
changes to their other medication), these rates did not 
diﬀ er overall (table 5).
Discussion
In this study of 82 627 patients prescribed antipsychotics 
and mood stabilisers over 4 years, we recorded an 
association between antipsychotic drugs and reductions 
in the rate of violent crime in the same people when they 
were on medication compared with when they were not. 
Importantly, our approach accounted for confounding 
factors that remained stable within the same patient. Our 
series of sensitivity analyses suggested similar rate 
reductions when any crime, less severe crime, drug-
related crime, and arrests on suspicion of violent crime 
were used as alternative outcomes, and in people without 
a history of violent crime. In addition to the apparently 
protective eﬀ ect of antipsychotic medication, we recorded 
similar ﬁ ndings for mood stabilisers, especially in patients 
with bipolar disorder. Although a direct causal 
interpretation is not possible, these associations might 
have important implications for clinical practice. The ﬁ rst 
and main such implication is that antipsychotics could 
have beneﬁ cial eﬀ ects on violent crime outcomes. Our 
results are consistent with a recent synthesis of trial data 
of ﬁ ve trials with 403 participants that suggested absolute 
reductions in rates of aggression from 12% to 2% in up to 
2 years of follow-up.8 We used harder outcomes, a longer 
follow-up, and a much larger sample size than did these 
trials (panel). Moreover, our data suggest that mood 
stabilisers could be used in a diﬀ erent way in clinical 
practice. As sole pharmacological agents, trial evidence 
has been ambiguous as to whether mood stabilisers 
reduce aggression or violence24,42 with no positive eﬀ ect 
recorded in higher quality studies.42 We report that people 
with bipolar disorder who take mood stabilisers have a 
reduced risk of committing violent crime, but these 
potential eﬀ ects of mood stabilisers were not demonstrated 
in people with schizophrenia or related psychoses.
Second, the addition of antipsychotics to mood 
stabilisers was more eﬀ ective than was a mood stabiliser 
alone, but the addition of a mood stabiliser to an 
antipsychotic did not have any eﬀ ect. In other words, for 
the patient with schizophrenia, the addition of a mood 
stabiliser does not seem warranted to reduce violence 
risk. This ﬁ nding is important because coadministration 
of antipsychotics and mood stabilisers is common in 
psychiatry53,54 despite an uncertain evidence base.25,45,55 For 
example, one US regional survey showed that 47% of 
8405 inpatients diagnosed with schizophrenia received a 
mood stabiliser.56 One concern about polypharmacy is 
the risk of side-eﬀ ects, especially metabolic ones, in 
patients with schizophrenia. These patients have high 
rates of all-cause mortality compared with the general 
population—a situation that seems to have worsened in 
recent decades.14 By contrast, if concerns exist about 
violence risk in a patient with bipolar disorder, the 
addition of an antipsychotic could be considered.
Third and ﬁ nally, our results suggest that associations 
exist between reductions in rates of violence and the use 
of depot antipsychotic drugs, and that this relation is at 
least as strong as for orally administered antipsychotics. 
The known beneﬁ ts of depot drugs for prevention of 
relapse28 have not been extended to include other 
outcomes.26 The potential reduction on violence risk will 
need to considered alongside less scope to titrate the 
dose, and low tolerability for some patients.57
Our research has some limitations. First, we did not 
investigate how the associations between medication and 
violent crime are mediated, and therefore we cannot 
assert causal eﬀ ects from our ﬁ ndings. Antipsychotic or 
mood-stabilising medication might lead to non-
pharmacological beneﬁ ts, such as more regular contact 
with health-care staﬀ , psychological interventions, or 
support from family and carers, and these indirect eﬀ ects 
might be what are actually being measured in our results. 
However, this limitation would not be consistent with the 
diﬀ erences reported by diagnosis and type of medication. 
For example, the indirect eﬀ ects of medication (such as 
increased support) would also be expected in those with 
schizophrenia who received mood stabilisers, in whom 
we did not record a signiﬁ cant rate reduction. 
Furthermore, we studied the eﬀ ects of being prescribed 
another oral drug, a selective serotonin reuptake inhibitor 
antidepressant, in this particular cohort and recorded no 
reduction in violence risk. A related threat to validity is 
reverse causality—that is, individuals who intend to 
commit crimes could stop taking their prescribed 
medication as part of a series of psychosocial changes 
that predate their crime, or they might receive treatment 
after a violent crime. However, this possibility would not 
be consistent with the analysis on the timing of 
medication (being on medication and then oﬀ , versus 
ﬁ rst being oﬀ  medication and then on) that led to similar 
results. If reverse causality was a major explanation, the 
latter pattern would not be signiﬁ cant. Additionally, since 
we included all violent crimes per individual, reverse 
causality would more clearly apply to those who 
committed only one violent crime during follow-up.
Another limitation is that confounding by indication 
can theoretically also occur between classes of psychotropic 
medication. For example, changes from antipsychotics to 
mood stabilisers and vice versa might occur depending on 
clinical severity, individual response to treatment, and 
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comorbidity. Moreover, our data are not sensitive enough 
to investigate disease phase (prodromal, acute, or chronic), 
which is an important area for future work. A further 
limitation is that we used violent conviction as our primary 
outcome. Violent conviction does not capture the violence 
that less often leads to arrest, including minor violence 
towards family members, social care and health-care 
professionals, and possibly other vulnerable people. 
Furthermore, the date of criminal behaviour based on 
conviction might have led to misclassiﬁ cation because an 
individual could have been behaving antisocially before 
this date. However, the use of violent convictions as an 
outcome is more generalisable than informant or self-
reported violence, and represents a higher public health 
burden to the individual and society in terms of costs, 
stigma, and possibly disease course than these other 
outcomes. Nevertheless, we also used data from the 
suspicions register to test the possibility that patients 
prescribed psychotropic medications might have their 
charges dropped more often than those without 
medications, and we did not record any noteworthy 
diﬀ erences in the eﬀ ects of medication on violent crime. 
Although our results were underpowered to assess 
clozapine, we did note a rate reduction using the 
suspicions register. Moreover, the analyses were based on 
dispensed prescriptions for medication (ie, those picked 
up by the individuals themselves, family members, or 
health-care staﬀ ) and we cannot be certain that these 
medications were actually taken by patients as intended 
(apart from the depots). However, this problem is similar 
to that in randomised controlled trials, in which intention-
to-treat analyses are mainly reported. The fact that some 
patients in our study probably did not take their medication 
as prescribed would reduce the drugs’ possible eﬀ ects on 
violent crime. Hence, we believe that our ﬁ ndings might 
be conservative estimates of the actual eﬀ ects of 
medication. One way to assess non-adherence was to 
compare the ﬁ rst 45 days after the start of treatment (when 
one would expect better adherence rates) with subsequent 
time (>45 days after initiation of treatment); however, we 
noted little diﬀ erence in rates of violence reduction by 
timing of medication initiation. Finally, we did not study 
polypharmacy beyond combination treatment of 
antipsychotics and mood stabilisers, and possible 
diﬀ erences in individual antipsychotics and mood 
stabilisers need further analysis.49 
We note that only about 40% of patients taking 
antipsychotics and mood stabilisers had a diagnosis of 
schizophrenia, other psychosis, or bipolar disorder, 
which means that these medications are used widely for 
other diagnostic groups and for patients without any 
formal psychiatric diagnosis, and could explain the 
recent large increases in their use.1 Nevertheless, the 
consistency of our ﬁ ndings across diagnostic boundaries 
suggests the mechanism of the antipsychotic action in 
risk reduction might not only include psychotic 
symptoms, but also behavioural traits of anger and 
hostility.58 Furthermore, mood stabilisers might act on 
mood instability, which are prominent in bipolar 
disorder and personality disorder, but also extend to 
subclinical problems.
An important issue is how generalisable our ﬁ ndings 
are to other countries. For example, according to data 
from the US Food and Drug Administration, monthly 
rates of antipsychotic prescriptions in US adults 
(>25 years of age) were 700–850 per 100 000 population in 
2004–06.59 This rate is not dissimilar to that in Sweden in 
2006 of 760 per 100 000 population. Although self-reported 
crime victimisation rates have been decreasing 
internationally, the UK, USA, and Sweden have fairly 
similar rates of violent crimes reported to the police, 
including assault, robbery, and rape, whereas rates of the 
most serious oﬀ ences (such as homicide) are substantially 
higher in the USA.60 In 2006, rates of assault recorded by 
the police in Sweden were 845 per 100 000 people 
compared with 787 per 100 000 in the USA.60 In England 
Panel: Research in context
Systematic review
We searched PubMed for published studies about the violence-reducing eﬀ ects of 
antipsychotics and mood stabilisers with the term “(antipsychotic* OR antimanic* OR 
mood stabiliser OR mood stabilizer OR antiepileptic*) AND (aggression OR violence OR 
crime OR oﬀ ending)” from Jan 1, 1966, up to Nov 28, 2013. We did not use any language 
or date restrictions, and we used “clinical trial”, “journal article”, “review”, and “humans” 
as ﬁ lters. The search yielded 1310 publications; of particular interest were seven recent 
systematic reviews about adults,8,12,24,42–45 three about children and adolescents,46–48 and one 
multi-group randomised controlled trial of adults.49
Existing evidence suggests that antipsychotics8 and valproate45 might reduce aggressive 
acts in patients with schizophrenia, but these studies are limited to aggression outcomes. 
Clozapine reportedly has stronger anti-aggressive qualities than other antipsychotics.43 
Uncertainty exists about whether ﬁ rst-generation or second-generation antipsychotics are 
more eﬀ ective,44,49 and regarding the use of depot versus oral medication in patients with 
schizophrenia.50 Antipsychotics and mood stabilisers reportedly reduced anger in some 
patients with borderline personality disorder.12 Risperidone might reduce aggression in 
young people to a greater extent than other antipsychotics in those with disruptive 
behaviour disorders47,48 and autism spectrum disorder.46 In the general population, mood 
stabilisers might reduce aggression24,42 but these eﬀ ects have not been proven in 
high-quality studies.
Interpretation
To our knowledge, this Article is the ﬁ rst total population-based study to address the 
potential violence-reducing eﬀ ects of antipsychotics and mood stabilisers with a 
within-individual research design. Although we cannot make direct causal interpretations, 
our ﬁ ndings suggest that the beneﬁ ts of antipsychotics might include eﬀ ects on various 
crime outcomes. This idea is consistent with the 83% relative reduction in aggression in 
schizophrenia reported in a recent synthesis of trial data.8 Furthermore, previous studies 
about whether pharmacological monotherapy with mood stabilisers reduces violence have 
been equivocal.51, 52 However, we reported that men with bipolar disorder who take mood 
stabilisers have a reduced rate of violent crime, but we recorded no such associations with 
mood stabilisers in patients with schizophrenia and related disorders. Our ﬁ ndings need 
additional conﬁ rmation in clinical trials and experimental studies but might be able to help 
management decisions for patients with psychiatric disorders.
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and Wales, the  rate was higher than in Sweden at 
1365 per 100 000 population in 2006.60
In summary, in this large population-wide study, we 
recorded reductions in violent crime in patients who 
were prescribed antipsychotics. Rates of violent crime 
were also reduced in patients with bipolar disorder who 
were receiving mood stabilisers. Therefore, in addition to 
the eﬀ ects of antipsychotics and mood stabilisers on 
relapse rates, their potential eﬀ ects on violence and 
crime should also be taken into account in decisions 
about management for these groups of patients.
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